2023 Rising Star in Industry Prize Winner
Dr Sam Staniland, AstraZeneca
Awarded for impact on the progression of multiple pharmaceutical projects by the application of bio- and chemocatalysis and high-throughput experimentation.
At AstraZeneca, Dr Staniland applies the latest technology to improve the way they make medicines. She particularly likes to use protein molecules called enzymes, which offer greener and more sustainable alternatives to make new drugs.
Year | Name | Institution | Citation |
2022 | Dr Stephen Hodge MRSC | Versarien plc | Awarded for strategic leadership in developing greener solutions and advocating for global regulations related to the physical and toxicological testing of graphene. |
2021 | Dr Stephen Dalby | MSD | Awarded for process innovation in novel drug development, transforming manufacturing route designs with improved sustainability. |
2020 | Dr Andy Chapman | Carbometrics Limited | Awarded for leading the scientific team of a small diabetes spin-out company towards one of the highest value exits for an early stage technology, and for pioneering new commercial opportunities with a second company founded after the acquisition. |
2019 |
Dr Alexander Reip | Oxford nanoSystems Ltd | Awarded for the creative development and scale-up of novel nano-coatings for energy saving and generation in heat transfer. |
2018 | Dr Andrew Pollard | National Physical Laboratory | Awarded for international leadership in industrially relevant measurements and standards for graphene and related 2D materials. |
2017 | Dr Jérémy Besnard | Exscientia Ltd | Awarded for the development of automated drug design algorithms that have delivered commercial value. |
2016 | Dr Angela Symington | BP | For her role in developing a framework to understand production chemistry threats relative to the design and delivery of major oil and gas projects. |
2015 | Dr Charlotte Hardy | GlaxoSmithKline | Awarded for her significant contribution to the delivery of three clinical candidates within the respiratory portfolio at GlaxoSmithKline. |
2014 | Dr Nathan Lawrence | University of Oxford | For outstanding achievements in analytical science relating to oil field exploration. |
2013 | Dr Gordon Saxty | Astex Pharmaceuticals Inc | For his original and innovative contributions to fragment based drug discovery resulting in multiple clinical candidates, highly regarded publications and an extensive list of patents. |
2012 | Dr Asier Unciti-Broceta | Deliverics | For his capacity to develop and lead the translation of novel concepts into products, along with his outstanding research/commercial early track record in the chemical sciences. |
2011 | Dr Martin Hanton | Sasol Technology UK | For his development of innovative homogeneous alkene di- and tetra-merisation initiator systems, which played a major contribution in developing one of the most important recent new processes in the petrochemical industry. |
2010 | Dr Jon-Paul Griffiths | Oxford Advanced Surfaces Group PLC | For his dedication and tenacity in researching novel applications of carbene chemistry which led to him setting up the spin-out Oxford Advanced Surfaces to exploit this new technology. |
2009 | Dr Lyn Jones | Pfizer | For his significant contribution to the early clinical portfolio at Pfizer. |
Re-thinking recognition: Science prizes for the modern world
This report is the result of an independent review of our recognition programmes. Our aim in commissioning this review was to ensure that our recognition portfolio continues to deliver the maximum impact for chemical scientists, chemistry and society.